Preclinical validation of the small molecule drug quininib as a novel therapeutic for colorectal cancer

Colorectal cancer (CRC) is a leading cause of cancer deaths. Molecularly targeted therapies (e.g. bevacizumab) have improved survival rates but drug resistance ultimately develops and newer therapies are required. We identified quininib as a small molecule drug with anti-angiogenic activity using in...

Descripción completa

Detalles Bibliográficos
Autores principales: Murphy, Adrian G., Casey, Rory, Maguire, Aoife, Tosetto, Miriam, Butler, Clare T., Conroy, Emer, Reynolds, Alison L., Sheahan, Kieran, O’Donoghue, Diarmuid, Gallagher, William M., Fennelly, David, Kennedy, Breandán N., O’Sullivan, Jacintha
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2016
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064353/
https://www.ncbi.nlm.nih.gov/pubmed/27739445
http://dx.doi.org/10.1038/srep34523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5064353/
https://www.ncbi.nlm.nih.gov/pubmed/27739445
http://dx.doi.org/10.1038/srep34523

Ejemplares similares